Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.
NCT02560337
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
26
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
Cabazitaxel
Sponsor
Vejle Hospital